Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness

Next Previous
X
Search
Trial Profile

A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efgartigimod alfa (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Proof of concept
  • Sponsors argenx

    • Most Recent Events

    • 27 Apr 2023 Results of pooled analysis (phase 2 myasthenia gravis, phase 2 open-label in pemphigus, ADAPT, ADVANCE, and ADAPT+) assessing the safety profile of efgartigimod across different IgG-mediated disorders, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
    • 22 May 2019 Results assessing safety and efficacy of efgartigimod in patients with generalized myasthenia gravis published in the Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top